Rhumbline Advisers Angion Biomedica Corp. Transaction History

Rhumbline Advisers

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$1.1 - $2.23 $12,868 - $26,088	-11,699 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$1.72 - $2.96 $1,293 - $2,225	752 Added 6.87%	11,699 $25,000
Q3 2021 Nov 12, 2021	BUY	$9.31 - $13.25 $101,916 - $145,047	10,947 New	10,947 $107,000

Ticker ANGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,113,300
Description
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primaril...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.